Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age

McDonald, 2006, The incidental postmenopausal adnexal mass, Clin Obstet Gynecol, 49, 506, 10.1097/00003081-200609000-00010

Yip, 2011, Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers, PLoS One, 6, e29533, 10.1371/journal.pone.0029533

Van Gorp, 2012, Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses, Eur J Cancer, 48, 1649, 10.1016/j.ejca.2011.12.003

Bast, 1981, Reactivity of a monoclonal antibody with human ovarian carcinoma, J Clin Invest, 68, 1331, 10.1172/JCI110380

Goonewardene, 2007, Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations, Lancet Oncol, 8, 813, 10.1016/S1470-2045(07)70273-5

Paramasivam, 2005, Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study, J Clin Oncol, 23, 5938, 10.1200/JCO.2005.08.151

Galgano, 2006, Comprehensive analysis of HE4 expression in normal and malignant human tissues, Mod Pathol, 19, 847, 10.1038/modpathol.3800612

Kirchhoff, 1991, A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors, Biol Reprod, 45, 350, 10.1095/biolreprod45.2.350

Drapkin, 2005, Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas, Cancer Res, 65, 2162, 10.1158/0008-5472.CAN-04-3924

Moore, 2008, Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus, Gynecol Oncol, 110, 196, 10.1016/j.ygyno.2008.04.002

Moore, 2009, A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass, Gynecol Oncol, 112, 40, 10.1016/j.ygyno.2008.08.031

Escudero, 2011, Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases, Clin Chem, 57, 1534, 10.1373/clinchem.2010.157073

Montagnana, 2011, The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?, Clin Chem Lab Med, 49, 521, 10.1515/CCLM.2011.075

Schummer, 2012, Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125, Gynecol Oncol, 125, 65, 10.1016/j.ygyno.2011.11.050

Li, 2012, Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and ca125 in predicting epithelial ovarian cancer: a meta-analysis, BMC Cancer, 12, 258, 10.1186/1471-2407-12-258

Merritt, 2008, Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer, Int J Cancer, 122, 170, 10.1002/ijc.23017

Nagle, 2011, Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group, J Clin Oncol, 29, 2253, 10.1200/JCO.2010.32.2164

Tothill, 2008, Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome, Clin Cancer Res, 14, 5198, 10.1158/1078-0432.CCR-08-0196

Hakansson, 2012, Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass, Acta Obstet Gynecol Scand, 91, 496, 10.1111/j.1600-0412.2012.01359.x

Jacobs, 1990, A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer, Br J Obstet Gynaecol, 97, 922, 10.1111/j.1471-0528.1990.tb02448.x

Chia, 2008, Triage of ovarian masses, Aust N Z J Obstet Gynaecol, 48, 322, 10.1111/j.1479-828X.2008.00825.x

Bandiera, 2011, Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management, Cancer Epidemiol Biomarkers Prev, 20, 2496, 10.1158/1055-9965.EPI-11-0635

Kim, 2011, Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case–control study in a Korean population, Clin Chem Lab Med, 49, 527, 10.1515/CCLM.2011.085

Lenhard, 2011, The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses, Clin Chem Lab Med, 49, 2081, 10.1515/CCLM.2011.709

Molina, 2011, HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases, Tumour Biol, 32, 1087, 10.1007/s13277-011-0204-3

Ruggeri, 2011, HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm, Clin Chim Acta, 412, 1447, 10.1016/j.cca.2011.04.028

Jacob, 2011, No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting, Gynecol Oncol, 121, 487, 10.1016/j.ygyno.2011.02.022

Van Gorp, 2011, HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm, Br J Cancer, 104, 863, 10.1038/sj.bjc.6606092

Wu, 2012, Diagnostic value of serum human epididymis protein 4 (HE4) in ovarian carcinoma: a systematic review and meta-analysis, Int J Gynecol Cancer, 22, 1106, 10.1097/IGC.0b013e318263efa2

Yu, 2012, Diagnostic value of HE4 for ovarian cancer: a meta-analysis, Clin Chem Lab Med, 50, 1439, 10.1515/cclm-2011-0477

Karlsen, 2012, Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass, Gynecol Oncol, 127, 379, 10.1016/j.ygyno.2012.07.106

Partheen, 2011, Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass, J Gynecol Oncol, 22, 244, 10.3802/jgo.2011.22.4.244

Zheng, 2012, Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease, Int J Gynecol Cancer, 22, 1000, 10.1097/IGC.0b013e318249bee7